Plain-spoken notes on the compounds we supply — what the literature shows, how to read a COA, and the protocols that protect your data. Cited, never hyped.
In the news
A listed telehealth company with 2.9 million subscribers is preparing to sell peptides, and is already running stability testing on BPC-157. What that says…
In the news
At the FDA's July 2026 compounding panel, six peptides passed and one failed: emideltide (DSIP). Why that single rejection is the most revealing vote…
In the news
Samsung Biologics has bid CHF 1.46bn for Swiss peptide CDMO PolyPeptide. A sober look at what the deal says about manufacturing capacity, and what…
In the news
Lilly's retatrutide passed TRIUMPH-2 and TRIUMPH-3 in July 2026 — but missed on cardiovascular events, and the FDA filing slipped to Q1 2027. An…
In the news
An FDA panel recommended six of seven peptides for the 503A compounding list on 23-24 July 2026. That is not approval. What the vote…
In the news
Which peptides Andrew Huberman has said he personally uses — pinealon, BPC-157, sermorelin — and what the primary literature actually shows about each.
In the news
Bryan Johnson has trialed CJC-1295, HGH, tirzepatide, cerebrolysin, epithalon, follistatin and BPC-157. A sourced look at what he measured, kept, and dropped.
In the news
Joe Rogan says he uses BPC-157 and TB-500 to heal injuries. We fact-check the claims against the actual literature — what holds up, what…
In the news
A source-checked look at where Peter Attia actually stands on NMN, rapamycin, metformin, GLP-1 drugs and BPC-157 — and where popular hype runs past…
In the news
A source-checked look at Gary Brecka's claims on methylene blue, BPC-157, NAD+ and hydrogen — what the literature actually shows, and where certainty outruns…
In the news
The GLP-1 shortage spawned a compounding boom. As the FDA winds it down, semaglutide is left as three distinct things that share a molecule's…
In the news
Retatrutide is a real phase III triple agonist that produced some of the largest weight-loss figures in trial history. The vial sold on a…
Occasional, considered notes on the compounds and the literature. No noise.
Subscribe & earn 500 pointsCookies
We use strictly necessary cookies to run the store. With your consent we also use analytics (order attribution) and marketing (Omnisend) cookies. Read our Cookie Policy.
